Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Raw Materials (2016 - 2020)

United Therapeutics' Raw Materials history spans 11 years, with the latest figure at $20.1 million for Q1 2020.

  • On a quarterly basis, Raw Materials fell 9.87% to $20.1 million in Q1 2020 year-over-year; TTM through Mar 2020 was $20.1 million, a 9.87% decrease, with the full-year FY2019 number at $21.1 million, down 13.17% from a year prior.
  • Raw Materials hit $20.1 million in Q1 2020 for United Therapeutics, down from $21.1 million in the prior quarter.
  • Over the last five years, Raw Materials for UTHR hit a ceiling of $29.1 million in Q2 2017 and a floor of $19.3 million in Q3 2019.
  • Historically, Raw Materials has averaged $24.4 million across 5 years, with a median of $24.8 million in 2016.
  • Biggest five-year swings in Raw Materials: increased 17.34% in 2017 and later dropped 25.77% in 2019.
  • Tracing UTHR's Raw Materials over 5 years: stood at $25.4 million in 2016, then rose by 9.84% to $27.9 million in 2017, then dropped by 12.9% to $24.3 million in 2018, then dropped by 13.17% to $21.1 million in 2019, then decreased by 4.74% to $20.1 million in 2020.
  • Business Quant data shows Raw Materials for UTHR at $20.1 million in Q1 2020, $21.1 million in Q4 2019, and $19.3 million in Q3 2019.